Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)

Inclusion Criteria: * Patients diagnosed with chronic hepatitis C * Among interferon-naïve patients, only patients with high viral load and HCV genotype other than 1 * Among prior nonresponders or relapsers to interferon monotherapy, (1) patients with high viral load and HCV genotype other than 1; and (2) patients with low viral load of all genotypes (including genotype 1) Exclusion Criteria: * Patients infected with HCV genotype 1 with high viral load, regardless of whether treatment-naïve or previous nonresponders/relapsers * Interferon-naïve patients with low viral load * Patients with a history of hypersensitivity to test drugs or other interferon preparations * Patients with a history of hypersensitivity to biological products, such as vaccines * Patients being treated with Shosaikoto * Patients with autoimmune hepatitis * Pregnant women, women who may be pregnant, and nursing mothers * Patients with a history of hypersensitivity to any component of this drug or other nucleoside analogs (aciclovir, ganciclovir, vidarabine, etc.) * Patients with difficult-to-control cardiac disease (eg, myocardial infarction, cardiac failure, arrhythmia) * Patients with hemoglobinopathies (eg, thalassemia, sickle-cell anemia) * Patients with chronic renal failure or renal function disorder with creatinine clearance of \<=50 mL/min * Patients with or a history of severe psychiatric condition such as severe depression, suicidal ideation or suicide attempt * Patients with serious hepatic dysfunction * Patients with autoimmune hepatitis